Breast implants face limited U.S. growth

The market for breast implants is expected to grow modestly in the U.S. over the nest few years, but European sales won't climb much at all, Millennium Research Group concludes in a new report. Among the factors leading to only modest U.S. sales: A rigorous U.S. approval process and a duopoly between the two main competitors--Allergan ($AGN) and Mentor. The EU market for breast implants remains much smaller, Millennium notes, and dipped by more than 2% from 2010 to 2011, with further declines expected through 2016. Release

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.